Combination Product Services Market (Focus on Particle Testing, Performance Testing and Product Development) by Type of Device (Autoinjectors, Prefilled Syringes, Large Volume Wearable Injectors and Other Types of Devices) Service Focus Area (Particle Testing, Performance Testing and Product Development), Company Size (Very Small, Small, Mid-sized, Large and Very Large Companies), and Key Geographical Regions (North America, Europe, Asia, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 5,899

  • Published
    August 2022

  • Pages
    185

  • View Count
    303

Example Insights

Combination-Product-Services-Market-Context-thumb Combination-Product-Services-Market-List-of-Combination-Product-Service-Providers-thumb Combination-Product-Services-Market-Type-of-Service-Offered-thumb
Combination-Product-Services-Market-Company-Competitiveness-Analysis-thumb Combination-Product-Services-Market-Distribution-by-Type-of-Expansion-thumb Combination-Product-Services-Market-Prefilled-Syringe-Combination-Products-thumb
Combination-Product-Services-Market-Distribution-by-Status-of-Development-thumb Combination-Product-Services-Market-Potential-Strategic-Developers-thumb Combination-Product-Services-Market-Combination-Products-Developers-thumb
Combination-Product-Services-Market-Distribution-by-Region-thumb    

Overview

Non-adherence to prescribed medication regimen is one of the major factors that not only causes negative implications on the patient’s health, but also adds to the overall pharmaceutical industry’s burden. According to an article published by Contract Pharma in April 2022, non-adherence to prescribed medicines is estimated to cost more than USD 250 billion annually to the drug developers. Further, lack of effective methods / solutions for sustained / controlled release of active pharmaceutical ingredient (API) at the targeted delivery sites is another challenge in efficient drug delivery. Notably, inadequate methods to control the release of API into the body cause fluctuations in plasma levels, leading to various side effects. Among other approaches used for efficient drug delivery, the introduction of combination products has garnered the attention of many developers within the pharmaceutical industry. Combination products comprise of two or more FDA- regulated components that provide controlled release of the APIs. However, the development of drug-device combination products is a long-drawn-out process that not only requires novel technologies and processes but also a huge amount of capital and expertise. In addition, drug-device compatibility, user needs, release testing / testing methods, production, and packaging requirements are other factors that add to complexity in commercialization of combination products. In order to overcoming these challenges and enhance patient experience, several combination product developers are outsourcing their operations to companies that offer services for testing and validating the efficacy of their combination products.

Presently, there are several combination product service providers which claim to employ various strategic approaches to support product development and testing to provide safe, effective combination products that meet user needs. These players provide the most suitable characterization methods that help manufacturers throughout the development and manufacturing process. Some of the common features provided by the combination product service providers include providing access to GMP-certified facilities, larger capacities, new technologies, and greater operational flexibility. Further, in order to address the existing challenges in combination product development and manufacturing, service providers are actively expanding their current geographical reach and broadening their respective services portfolio. With rising need for effective drug delivery in terms of controlled drug release and the increased focus of service providers towards the development and commercial manufacturing of combination products, the combination product services market is likely to witness a significant growth in the coming years.

Scope of the Report

The “Combination Product Services Market (Focus on Particle Testing, Performance Testing and Product Development)  by Type of Device (Autoinjectors, Prefilled Syringes, Large Volume Wearable Injectors and Other Types of Devices) Service Focus Area (Particle Testing, Performance Testing and Product Development), Company Size (Very Small, Small, Mid-sized, Large and Very Large Companies), and Key Geographical Regions (North America, Europe, Asia, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035” report features an extensive study of service providers engaged in development and testing of combination products. The study features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain. Amongst other elements, the report features:

  • A detailed assessment of the market landscape of combination product service providers based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized, large and very large), location of headquarters, type of combination product(s) (drug delivery device / system, device coated / impregnated with drug, and  other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s) (particle testing, performance testing, and product development), type of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), location of facility and leading players (in terms of number of services offered). 
  • A detailed company competitiveness analysis of combination product service providers, based on supplier power (based on the experience of the developer in this industry) and service portfolio strength based on several relevant parameters, such as type of combination product(s) (device coated / impregnated with drug, drug delivery device / system, and other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s), (particle testing, performance testing, and product development), types of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), and number of accreditations / certifications.
  • Elaborate profiles of key players that offer services for development and testing of combination products. Each profile features a brief overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, recent developments and an informed future outlook.
  • A detailed analysis of the recent expansions undertaken by various combination product service providers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility addition), location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.
  • A case study on most advanced and popular combination products, including large volume wearble injectors and prefilled syringes combination products, providing information on their developer(s) and combination product specific features. Details of specific parameters captured for different product categories are mentioned as follows:
  • Large Volume Wearble Injector Combination Products: These products have been analyzed based on phase of development, type of device, drug compatibility, type of dosage, route of administration, method of administration, therapeutic area, storage volume / capacity, usability, technology used, mechanism of action and type of drug container.
  • Prefilled Syringe Combination Products: These therapies that have been approved / are being developed in combination with prefilled syringes have been analyzed based on type of drug molecule,  year of approval (for approved therapies), geography (for approved therapies), route of administration, therapeutic area, dose strength (for approved therapies), and other available dosage forms (for approved therpies).
  • A list of more than 90 combination product developers that are likely to partner with combination product service providers (with regard to likely collaboration opportunities for combination product development and testing). These players have been shortlisted based on various parameters, such as pipeline strength, developer strength and product strength.
  • An insightful outsourcing: go or no go framework analysis, highlighting the various factors that need to be taken into consideration by combination product developers while deciding whether to develop their respective products in-house or engage the services of a service provider. Further, the analysis highlights all the key parameters that must be considered by players based on company sizes (very small, small, mid-sized, and large), while taking the aforementioned decision.

One of the key objectives of the report was to evaluate the existing market size, primary growth factors and future opportunity within the combination product service providers market in the mid to long term. Our year-wise projections of the current and future opportunity within the combination product service providers market have further been segmented across types of devices (autoinjectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus areas (particle testing, performance testing and product development), company size (very small, small, mid-sized, large and very large), and key geographical regions (North America, Europe, Asia and rest of the world). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry.

Key Questions Answered

  • Who are the key players that provide services for the development and testing of combination products?
  • What are the most common services offered by combination product service providers?
  • What are the different types of expansion initiatives being undertaken by combination product service providers?
  • Who are the leading players that are currently engaged in the development / commercialization of combination products?
  • What are the most advanced features of combination products?
  • Which factors are likely to influence the decision of combination product developers for outsourcing development and testing operations?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the combination product service providers market and its likely evolution in the mid to long term.

Chapter 3 provides an overview of combination products, along with information on various types of combination products. Additionally, it includes information on the various challenges associated with development and testing of combination products. Further, it features a brief discussion on the growing need for outsourcing within this domain.

Chapter 4 provides a detailed review of the overall landscape of combination product service providers along with information on over 25 service providers that claim to provide development and testing services for combination products. Additionally, it features an in-depth analysis of service providers, based on several relevant parameters, such as year of establishment, company size (very small, small, mid-sized, large and very large), location of headquarters, type of combination product(s) (drug delivery device / system, device coated / impregnated with drug, and  other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s) (particle testing, performance testing, and product development), type of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), location of facility and leading players (in terms of number of services offered).

Chapter 5 features a detailed company competitiveness analysis of the combination product service providers, based on several relevant parameters, such as supplier power (based on the experience of the developer in this industry) and service portfolio strength based on several relevant parameters, such as type of combination product(s) (device coated / impregnated with drug, drug delivery device / system, and other types of combination products), type of device(s) (autoinjectors, pen-injectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus area(s), (particle testing, performance testing, and product development), types of service(s) offered (chemical characterization / testing, closure integrity testing, packaging validation, process development and validation, stability studies and other types of services), and number of accreditations / certifications.
 
Chapter 6 provides detailed profiles of the key players (shortlisted based on a proprietary criterion) that are active in the combination product services market. Each profile provides an overview of the company, along with information on year of establishment, location of headquarters, number of employees, key executives, details on recent developments, and an informed future outlook.

Chapter 7 presents a detailed analysis of the recent expansions undertaken by various combination product service providers, based on several relevant parameters, such as year of expansion, type of expansion (capacity expansions, facility expansions and new facility additions), location of expanded facility, most active players (in terms of number of recent expansions) and geographical distribution.

Chapter 8 features an elaborate discussion on combination products, with special focus on large volume wearable injectors and  prefilled syringes. The chapter includes a detailed analysis based on specific parameters for each product category, namely [A] large volume wearable injector combination products based on their phase of development, type of device, drug compatibility, type of dosage, route of administration, method of administration, therapeutic area, storage volume / capacity, usability, technology used, mechanism of action and type of drug container and [B] prefilled syringe combination products (therapies that have approved / are being developed in combination prefilles syringes) based on type of drug molecule,  year of approval (for approved therapies), geography (for approved therapies), route of administration, therapeutic area, dose strength (for approved therapies), and other available dosage forms (for approved therapies).

Chapter 9 features a list of 90+ stakeholders that are anticipated to partner with combination product service providers in the foreseen future. The players have been shortlisted based on a detailed analysis of relevant parameters, namely pipeline strength (in terms of number of product that have been / are being developed by the player), developer strength (based on player’s experience in the domain) and product strength.

Chapter 10 presents an insightful analysis that highlights the various factors that need to be taken into consideration by combination product developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO. Further, the analysis highlights all the key parameters that must be considered by players of different company sizes (very small, small, mid-sized, and large) while taking the aforementioned decision.

Chapter 11 features a comprehensive market forecast analysis, highlighting the likely growth of the combination product services market, for the period 2022-2035. Additionally, the report features the likely distribution of the current and forecasted opportunity across types of devices (autoinjectors, prefilled syringes, large volume wearable injectors and other types of devices), service focus areas (particle testing, performance testing and product development), company size (very small, small, mid-sized, large and very large), and key geographical regions (North America, Europe, Asia, and rest of the world).

Chapter 12 is a summary of the entire report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 13 provides the transcripts of interviews conducted with representatives from renowned organizations, which are engaged in the domain of combination product services. 

Chapter 14 is an appendix, that provides tabulated data and numbers for all the figures included in the report.

Chapter 15 is an appendix that provides the list of companies and organizations that have been mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Combination Products
3.3. Challenges Associated with Development of Combination Products
3.4. Outsourced Combination Products Operations / Services
3.5. Advantages of Outsourcing Operations for Combination Products
3.6. Key Considerations while Selecting a CDMO
3.7. Future Perspectives

4. COMBINATION PRODUCTS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Combination Products Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Type of Combination Product
4.2.5. Analysis by Type of Device
4.2.6. Analysis by Service Focus Area(s)
4.2.7. Analysis by Type of Service(s) Offered
4.2.8. Analysis by Location of Facility
4.2.9. Leading Combination Products Service Providers: Analysis by Number ofService(s) Offered
4.2.10. 4D Bubble Representation: Analysis by Company Size, Location of Headquarters(Region), Number of Service Focus Area(s) and Number of Service(s) Offered
4.2.11. Mekko Representation: Analysis by Company Size and Number of Service Focus Area(s)

5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Assumptions / Key Parameters
5.3. Methodology
5.4. Combination Products Service Providers: Company Competitiveness Analysis
5.4.1. Combination Products Service Providers based in North America
5.4.2. Combination Products Service Providers based in Europe and Asia

6. COMBINATION PRODUCTS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. EKG LABS
6.2.1. Company Overview
6.2.2. Recent Developments and Future Outlook

6.3. Eurofins Medical Device Testing
6.3.1. Company Overview
6.3.2. Recent Developments and Future Outlook

6.4. Exponent
6.4.1. Company Overview
6.4.2. Recent Developments and Future Outlook

6.5. Kymanox
6.5.1. Company Overview
6.5.2. Recent Developments and Future Outlook

6.6. Medical Engineering Technologies
6.6.1. Company Overview
6.6.2. Recent Developments and Future Outlook

6.7. Pace Analytical Services
6.7.1. Company Overview
6.7.2. Recent Developments and Future Outlook

6.8. Suttons Creek
6.8.1. Company Overview
6.8.2. Recent Developments and Future Outlook

6.9. West Pharmaceutical Services
6.9.1. Company Overview
6.9.2. Recent Developments and Future Outlook

6.10. Concluding Remarks: Initiatives Undertaken by Industry Players

7. RECENT EXPANSIONS
7.1. Chapter Overview
7.2. Combination Products Service Providers: List of Recent Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Location of Expanded Facility
7.2.4. Analysis by Type of Expansion (Country-wise)
7.2.5. Most Active Players: Analysis by Number of Expansions
7.2.6. Geographical Analysis

8. CASE STUDY: LARGE VOLUME WEARABLE INJECTORS AND PREFILLED SYRINGES COMBINATION PRODUCTS
8.1. Chapter Overview
8.2. Large Volume Wearable Injector Combination Products
8.2.1. Large Volume Drug Device Combination Products: Market Landscape
8.2.1.1. Analysis by Phase of Development
8.2.1.2. Analysis by Type of Device
8.2.1.3. Analysis by Drug Compatibility
8.2.1.4. Analysis by Type of Dosage
8.2.1.5. Analysis by Route of Administration
8.2.1.6. Analysis by Method of Administration
8.2.1.7. Analysis by Therapeutic Area
8.2.1.8. Analysis by Storage Volume / Capacity
8.2.1.9. Analysis by Usability
8.2.1.10. Analysis by Technology Used
8.2.1.11. Analysis by Mechanism of Action
8.2.1.12. Analysis by Type of Drug Container

8.2.2. Large Volume Drug Device Combination Products: Developer Landscape
8.2.2.1. Analysis by Year of Establishment
8.2.2.2. Analysis by Company Size
8.2.2.3. Analysis by Location of Headquarters
8.2.2.4. Most Active Players: Analysis by Number of Products Manufactured

8.3. Prefilled Syringes Combination Products
8.3.1. Prefilled Syringe Combination Products: List of Approved Drugs, 2013-2021
8.3.1.1. Analysis by Type of Drug Molecule
8.3.1.2. Analysis by Approval Year
8.3.1.3. Analysis by Geography
8.3.1.4. Analysis by Route of Administration
8.3.1.5. Analysis by Therapeutic Area
8.3.1.6. Analysis by Dosage Strength
8.3.1.7. Analysis by Other Approved Dosage Forms

8.3.2. Prefilled Syringe Combination Products: List of Clinical Stage Drugs
8.3.2.1. Analysis by Type of Drug Molecule
8.3.2.2. Analysis by Phase of Development
8.3.2.3. Analysis by Route of Administration
8.3.2.4. Analysis by Therapeutic Area

8.3.3. Prefilled Syringes Combination Products: Information on Developers
8.3.3.1. Analysis by Year of Establishment
8.3.3.2. Analysis by Company Size
8.3.3.3. Analysis by Location of Headquarters

9. LIKELY PARTNER ANALYSIS
9.1. Chapter Overview
9.2. Large Volume Wearable Injectors Combination Products
9.2.1. Scoring Criteria and Key Assumptions
9.2.2. Scope and Methodology
9.2.3. Potential Strategic Partners
9.2.3.1. Most Likely Partners
9.2.3.2. Likely Partners
9.2.3.3. Less Likely Partners
9.3. Prefilled Syringes Combination Products
9.3.1. Scoring Criteria and Key Assumptions
9.3.2. Scope and Methodology
9.3.3. Potential Strategic Partners
9.3.3.1. Most Likely Partners
9.3.3.2. Likely Partners
9.3.3.3. Less Likely Partners

10. OUTSOURCING: GO / NO-GO FRAMEWORK
10.1. Chapter Overview
10.2. Outsourcing: Go / No-Go Framework
10.3. Prefilled Syringes Combination Products Developers: Go / No-Go Framework
10.3.1. Assumptions and Key Parameters
10.3.2. Methodology
10.3.3. Results and Interpretations
10.3.3.1. Outsourcing: Go / No-Go Framework for Very Small and Small Companies
10.3.3.2. Outsourcing: Go / No-Go Framework for Mid-sized Companies
10.3.3.3. Outsourcing: Go / No-Go Framework for Large Companies

11. MARKET FORECAST
11.1. Chapter Overview
11.2. Key Assumptions and Forecast Methodology
11.3. Global Combination Products Service Providers Market, 2022-2035
11.3.1. Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035
11.3.1.1. Combination Products Service Providers Market for Large Volume Wearable Injectors
11.3.1.2. Combination Products Service Providers Market for Autoinjector Combination Products
11.3.1.3. Combination Products Service Providers Market for Prefilled Syringe
11.3.1.4. Combination Products Service Providers Market for Other Types of Combination Products

11.3.2. Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035
11.3.2.1. Combination Products Service Providers Market for Particle Testing
11.3.2.2. Combination Products Service Providers Market for Performance Testing
11.3.2.3. Combination Products Service Providers Market for Product Development

11.3.3. Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035
11.3.3.1. Combination Products Service Providers Market for Very Small Companies
11.3.3.2. Combination Products Service Providers Market for Small Companies
11.3.3.3. Combination Products Service Providers Market for Mid-sized Companies
11.3.3.4. Combination Products Service Providers Market for Large Companies
11.3.3.5. Combination Products Service Providers Market for Very Large Companies

11.3.4 Combination Products Service Providers Market: Distribution by Region, 2022 and 2035
11.3.4.1. Combination Products Service Providers Market in North America, 2022-2035
11.3.4.2. Combination Products Service Providers Market in Europe, 2022-2035
11.3.4.3. Combination Products Service Providers Market in Asia, 2022-2035
11.3.4.4. Combination Products Service Providers in Rest of the World, 2022-2035

12. CONCLUDING REMARKS

13. EXECUTIVE INSIGHTS

14. APPENDIX 1: TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary: Combination Products Service Providers Market Landscape
Figure 2.2 Executive Summary: Recent Expansions
Figure 2.3 Executive Summary: Case Study on Large Volume Wearable Injectors and Prefilled Syringes Combination Products
Figure 2.4 Executive Summary: Market Forecast
Figure 3.1 Types of Combination Products
Figure 3.2 Recently Approved Combination Products
Figure 3.3 Challenges Associated with Development of Combination Products
Figure 3.4 Key Outsourced Combination Product Operations / Services
Figure 4.1 Combination Products Service Providers: Distribution by Year of Establishment
Figure 4.2 Combination Products Service Providers: Distribution by Company Size
Figure 4.3 Combination Products Service Providers: Distribution by Location of Headquarters
Figure 4.4 Combination Products Service Providers: Distribution by Company Size and Location of Headquarters
Figure 4.5 Combination Products Service Providers: Distribution by Type of Combination Product
Figure 4.6 Combination Products Service Providers: Distribution by Company Size and Type of Combination Product
Figure 4.7 Combination Products Service Providers: Distribution by Type of Device
Figure 4.8 Combination Product Service Providers: Distribution by Service Focus Area(s)
Figure 4.9 Combination Product Service Providers: Distribution by Type of Service(s) Offered
Figure 4.10 Combination Product Service Providers: Distribution by Location of Facility (Region-wise)
Figure 4.11 Combination Product Service Providers: Distribution by Location of Facility (Country-wise)
Figure 4.12 Leading Combination Products Service Providers: Distribution by Number of Service(s) Offered
Figure 4.13 4D Bubble Representation: Distribution by Company Size, Location of Headquarters (Region), Number of Service Focus Area(s) and Number of Service(s) Offered
Figure 4.14 Mekko Representation: Distribution by Company Size and Service Focus Area(s)
Figure 5.1 Company Competitiveness Analysis: Players based in North America
Figure 5.2 Company Competitiveness Analysis: Players based in Europe and Asia
Figure 6.1 Company Profiles: Initiatives Undertaken by Industry Players
Figure 7.1 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 7.2 Recent Expansions: Distribution by Type of Expansion
Figure 7.3 Recent Expansions: Distribution by Year of Expansion and Type of Expansion
Figure 7.4 Recent Expansions: Distribution by Location of Expanded Facility
Figure 7.5 Recent Expansions: Distribution by Type of Expansion (Country-wise)
Figure 7.6 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion (Country-wise)
Figure 7.7 Most Active Players: Distribution by Number of Expansions
Figure 9.1 Large Volume Drug Device Combination Products: Distribution by Phase of Development
Figure 9.2 Large Volume Drug Device Combination Products: Distribution by Type of Device
Figure 9.3 Large Volume Drug Device Combination Products: Distribution by Mechanism of Action
Figure 9.4 Large Volume Drug Device Combination Products: Distribution by Type of Technology Used
Figure 9.5 Large Volume Drug Device Combination Products: Distribution by Route of Administration
Figure 9.6 Large Volume Drug Device Combination Products: Distribution by Method of Administration
Figure 9.7 Large Volume Drug Device Combination Products: Distribution by Therapeutic Area
Figure 9.8 Large Volume Drug Device Combination Products: Distribution by Type of Dosage
Figure 9.9 Large Volume Drug Device Combination Products: Distribution by Storage Volume / Capacity (in mL)
Figure 9.10 Large Volume Drug Device Combination Products: Distribution by Usability
Figure 9.11 Large Volume Drug Device Combination Products: Distribution by Drug ompatibility
Figure 9.12 Large Volume Drug Device Combination Products: Distribution by Drug Container
Figure 9.13 Large Volume Drug Device Combination Products Developers: Distribution by Year of Establishment
Figure 9.14 Large Volume Drug Device Combination Products Developers: Distribution by Company Size
Figure 9.15 Large Volume Drug Device Combination Products: Distribution by Location of Headquarters
Figure 9.16 Most Active Players: Distribution by Number of Products Manufactured
Figure 9.17 Approved Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Figure 9.18 Approved Prefilled Syringes Combination Products: Distribution by Approval Year
Figure 9.19 Approved Prefilled Syringes Combination Products: Distribution by Geography
Figure 9.20 Approved Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.21 Approved Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Figure 9.22 Approved Prefilled Syringes Combination Products: Distribution by Other Dosage Forms
Figure 9.23 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Figure 9.24 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
Figure 9.25 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
Figure 9.26 Clinical Stage Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Figure 9.27 Prefilled Syringes Combination Product Developers: Distribution by Year of Establishment
Figure 9.28 Prefilled Syringes Combination Product Developers: Distribution by Company Size
Figure 9.29 Prefilled Syringes Combination Product Developers: Distribution by Location of Headquarters
Figure 10.1 Outsourcing: Go / No-Go Framework
Figure 10.2 Outsourcing: Go / No-Go Framework for Prefilled Syringes CombinationProduct Developers
Figure 10.3 Prefilled Syringes Combination Products Developers: Benchmarking of Very Small / Small Companies
Figure 10.4 Prefilled Syringes Combination Products Developers: Benchmarking of Mid-sized Companies
Figure 10.5 Prefilled Syringes Combination Products Developers: Benchmarking of Large Companies
Figure 11.1 Global Combination Products Service Providers Market, 2022-2035 (USD Million)
Figure 11.2 Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035 (USD Million)
Figure 11.3 Combination Products Service Providers Market for Large Volume Wearable Injectors, 2022-2035 (USD Million)
Figure 11.4 Combination Products Service Providers Market for Autoinjector, 2022-2035 (USD Million)
Figure 11.5 Combination Products Service Providers Market for Prefilled Syringes, 2022-2035 (USD Million)
Figure 11.6 Combination Products Service Providers Market for Other Types of Combination Products, 2022-2035 (USD Million)
Figure 11.7 Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035 (USD Million)
Figure 11.8 Combination Products Service Providers Market for Particle Testing, 2022-2035 (USD Million)
Figure 11.9 Combination Products Service Providers Market for Performance Testing2022-2035 (USD Million)
Figure 11.10 Combination Products Service Providers Market for Product Development, 2022-2035 (USD Million)
Figure 11.11 Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035 (USD Million)
Figure 11.12 Combination Products Service Providers Market for Very Small Companies, 2022-2035 (USD Million)
Figure 11.13 Combination Products Service Providers Market for Small Companies, 2022-2035 (USD Million)
Figure 11.14 Combination Products Service Providers Market for Mid-sizedCompanies 2022-2035 (USD Million)
Figure 11.15 Combination Products Service Providers Market for Large Companies, 2022-2035 (USD Million)
Figure 11.16 Combination Products Service Providers Market for Very LargeCompanies 2022-2035 (USD Million)
Figure 11.17 Global Combination Products Service Providers Market: Distribution by Region, 2022 and 2035 (USD Million)
Figure 11.18 Combination Products Service Providers Market in North America, 2022-2035 (USD Million)
Figure 11.19 Combination Products Service Providers Market in Europe, 2022-2035 (USD Million)
Figure 11.20 Combination Products Service Providers Market in Asia, 2022-2035 (USD Million)
Figure 11.21 Combination Products Service Providers Market in Rest of the World, 2022-2035 (USD Million)
Figure 12.1 Conclusion: Combination Products Service Providers Market Landscape
Figure 12.2 Conclusion: Company Competitiveness Analysis
Figure 12.3 Conclusion: Recent Expansions
Figure 12.4 Conclusion: Combination Products Case Study on Large Volume Wearable Injectors and Prefilled Syringes
Figure 12.5 Conclusion: Likely Partner Analysis
Figure 12.6 Conclusion: Outsourcing Go / No-Go Framework
Figure 12.7 Conclusion: Market Forecast

List Of Tables

Table 4.1 Combination Products Service Providers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 4.2 Combination Products Service Providers: Information on Type of Combination Product
Table 4.3 Combination Products Service Providers: Information on Type of Device
Table 4.4 Combination Products Service Providers: Information on Service Focus Area(s)
Table 4.5 Combination Products Service Providers: Information on Type of Service(s) Offered
Table 4.6 Combination Products Service Providers: Information on Location of Facility(s)
Table 6.1 Combination Products Service Providers: List of Companies Profiled
Table 6.2 EKG LABS: Company Overview
Table 6.3 Eurofins Medical Device Testing: Company Overview
Table 6.4 Eurofins Medical Device Testing: Recent Developments and Future Outlook
Table 6.5 Exponent: Company Overview
Table 6.6 Exponent: Recent Developments and Future Outlook
Table 6.7 Kymanox: Company Overview
Table 6.8 Kymanox: Recent Developments and Future Outlook
Table 6.9 Medical Engineering Technologies: Company Overview
Table 6.10 Medical Engineering Technologies: Recent Developments and Future Outlook
Table 6.11 Pace Analytical Services: Company Overview
Table 6.12 Pace Analytical Services: Recent Developments and Future Outlook
Table 6.13 Suttons Creek: Company Overview
Table 6.14 Suttons Creek: Recent Developments and Future Outlook
Table 6.15 West Pharmaceutical Services: Company Overview
Table 6.16 West Pharmaceutical Services: Recent Developments and Future Outlook
Table 7.1 Combination Products Service Providers: List of Expansions, 2017-2022
Table 8.1 Large Volume Drug Device Combinations: Information on Phase of Development and Device Features
Table 8.2 Large Volume Drug Device Combinations: Information on Drug Administration Related Parameters
Table 8.3 Large Volume Wearable Injectors for Drug Device Combinations: Information on Developers
Table 8.4 Prefilled Syringes Combination Products: List of Approved Drugs, 2013-2021
Table 8.5 Prefilled Syringes Combination Products: Information on Approval Year, 2013-2021
Table 8.6 Prefilled Syringes Combination Products: Information on Target Indication(s) and Dosage Strength
Table 8.7 Prefilled Syringes Combination Products: List of Other Drug Delivery Solutions, 2013-2021
Table 8.8 Prefilled Syringes Combination Products: List of Clinical Stage Drugs
Table 8.9 Prefilled Syringes Combination Products: List of Developers
Table 9.1 Most Likely Partners
Table 9.2 Likely Partners
Table 9.3 Least Likely Partners
Table 14.1 Combination Products Service Providers: Cumulative Distribution by Year of Establishment
Table 14.2 Combination Products Service Providers: Distribution by Company Size
Table 14.3 Combination Products Service Providers: Distribution by Location of Headquarters
Table 14.4 Combination Products Service Providers: Distribution by Company Size and Location of Headquarters
Table 14.5 Combination Products Service Providers: Distribution by Type of Combination Product
Table 14.6 Combination Products Service Providers: Distribution by Company Size and Type of Combination Product
Table 14.7 Combination Products Service Providers: Distribution by Type of Device
Table 14.8 Combination Product Service Providers: Distribution by Service Focus Area(s)
Table 14.9 Combination Product Service Providers: Distribution by Type of Service(s) Offered
Table 14.10 Combination Product Service Providers: Distribution by Location of Facility (Region-wise)
Table 14.11 Combination Product Service Providers: Distribution by Location of Facility (Country-wise)
Table 14.12 Leading Combination Product Service Providers: Distribution by Number of Key Service(s) Offered
Table 14.13 4D Bubble Analysis: Distribution by Company Size, Company Headquarters (Region), Number of Service Focus Area(s) and Number of
Table 14.14 Meko Representation: Distribution by Company Size and Service Focus Area(s)
Table 14.15 Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 14.16 Recent Expansions: Distribution by Type of Expansion
Table 14.17 Recent Expansions: Distribution by Year of Expansion and Type of Expansion
Table 14.18 Recent Expansions: Distribution by Location of Expanded Facility
Table 14.19 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 14.20 Recent Expansions: Distribution by Type of Expansion (Country-wise)
Table 14.21 Recent Expansions: Distribution by Location of Expanded Facility and Type of Expansion (Country-wise)
Table 14.22 Most Active Players: Distribution by Number of Recent Expansions
Table 14.23 Large Volume Drug Device Combinations: Distribution by Phase of Development
Table 14.24 Large Volume Drug Device Combinations: Distribution by Type of Device
Table 14.25 Large Volume Drug Device Combinations: Distribution by Mechanism of Action
Table 14.26 Large Volume Drug Device Combinations: Distribution by Type of Technology Used
Table 14.27 Large Volume Drug Device Combinations: Distribution by Route of Administration
Table 14.28 Large Volume Drug Device Combinations: Distribution by Method of Administration
Table 14.29 Large Volume Drug Device Combinations: Distribution by Therapeutic Area
Table 14.30 Large Volume Drug Device Combinations: Distribution by Type of Dosage
Table 14.31 Large Volume Drug Device Combinations: Distribution by Storage Volume / Capacity (in mL)
Table 14.32 Large Volume Drug Device Combinations: Distribution by Usability
Table 14.33 Large Volume Drug Device Combinations: Distribution by Drug Compatibility
Table 14.34 Large Volume Drug Device Combinations: Distribution by Drug Container
Table 14.35 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Year of Establishment
Table 14.36 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Company Size
Table 14.37 Large Volume Wearable Injectors for Drug Device Combinations: Distribution of Developers by Location of Headquarters
Table 14.38 Leading Players: Distribution by Number of Products
Table 14.39 Approved Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Table 14.40 Approved Prefilled Syringes Combination Products: Distribution by Approval Year
Table 14.41 Approved Prefilled Syringe Combination Products: Distribution by Geography
Table 14.42 Approved Prefilled Syringe Combination Products: Distribution by Route of Administration
Table 14.43 Approved Prefilled Syringe Combination Products: Distribution by Therapeutic Area
Table 14.44 Approved Prefilled Syringe Combination Products: Distribution by Other Dosage Forms
Table 14.45 Clinical Stage Prefilled Syringes Combination Products: Distribution by Type of Drug Molecule
Table 14.46 Clinical Stage Prefilled Syringes Combination Products: Distribution by Phase of Development
Table 14.47 Clinical Stage Prefilled Syringes Combination Products: Distribution by Route of Administration
Table 14.48 Clinical Stage Prefilled Syringes Combination Products: Distribution by Therapeutic Area
Table 14.49 Prefilled Syringe Combination Product Developers: Distribution by Year of Establishment
Table 14.50 Prefilled Syringe Combination Product Developers: Distribution by Company Size
Table 14.51 Prefilled Syringe Combination Product Developers: Distribution by Location of Headquarters
Table 14.52 Global Combination Products Service Providers Market, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.53 Global Combination Products Service Providers Market: Distribution by Type of Device, 2022 and 2035
Table 14.54 Combination Products Service Providers Market for Large Volume Wearable Injectors, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.55 Combination Products Service Providers Market for Autoinjectors, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.56 Combination Products Service Providers Market for Prefilled Syringes, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.57 Combination Products Service Providers Market for Other Types of Combination Products, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.58 Global Combination Products Service Providers Market: Distribution by Service Focus Area, 2022 and 2035
Table 14.59 Combination Products Service Providers Market for Particle Testing, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.60 Combination Products Service Providers Market for Performance Testing2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.61 Combination Products Service Providers Market for Product Development, 2022-2035 (USD Million), Conservative, Base and
Table 14.62 Global Combination Products Service Providers Market: Distribution by Company Size, 2022 and 2035
Table 14.63 Combination Products Service Providers Market for Very Small Companies, 2022-2035 (USD Million), Conservative, Base and
Table 14.64 Combination Products Service Providers Market for Small Companies, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.65 Combination Products Service Providers Market for Mid-sizedCompanies 2022-2035 (USD Million), Conservative, Base and Optimistic
Table 14.66 Combination Products Service Providers Market for Large Companies, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.67 Combination Products Service Providers Market for Very LargeCompanies 2022-2035 (USD Million), Conservative, Base and Optimistic
Table 14.68 Global Combination Products Service Providers Market: Distribution by Region, 2022 and 2035
Table 14.69 Combination Products Service Providers Market in North America, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.70 Combination Products Service Providers Market in Europe, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.71 Combination Products Service Providers Market in Asia, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios
Table 14.72 Combination Products Service Providers Market in Rest of the World, 2022-2035 (USD Million), Conservative, Base and Optimistic Scenarios

List Of Companies

The following companies and organizations have been mentioned in the report:

  1. Angiplast
  2. 3M
  3. Abbott Laboratories
  4. AbbVie
  5. Accord Healthcare
  6. Adamis Pharmaceuticals 
  7. Adimmune
  8. Alder BioPharmaceuticals
  9. Alkermes
  10. Alvogen
  11. Alvotech
  12. Amgen
  13. Amgen
  14. Amphastar Pharmaceuticals
  15. anteris medical
  16. Apobiologix
  17. Asarina Pharma
  18. AstraZeneca
  19. B.Braun
  20. Basic Laboratory
  21. BD
  22. Bio-Concept Laboratories
  23. Biogen
  24. Bioinova
  25. Boehringer Ingelheim
  26. Bone Therapeutics
  27. Braeburn Pharmaceuticals
  28. Bristol-Myers Squibb
  29. Camurus
  30. Celltrion
  31. Centrexion Therapeutics
  32. Chugai Pharmaceuticals
  33. Coherus BioSciences
  34. Con-Test Analytical Laboratory (Acquired by Pace Analytical® Services)
  35. Cumberland Pharmaceuticals
  36. Cycle Pharmaceuticals
  37. DDL
  38. Department of Defense 
  39. Drug Delivery Experts
  40. Dynavax Technologies
  41. EdgeOne Medical
  42. EKG Labs
  43. Element Materials Technology
  44. Eli Lilly
  45. EMD Serono
  46. Emerson Resources (Acquired by Pace Analytical® Services)
  47. Eurofins Medical Device Testing
  48. EVER Pharma
  49. Exemplar Compliance
  50. Exponent
  51. Foresee Pharmaceuticals
  52. Fresenius Kabi
  53. Fujifilm
  54. GC Pharma
  55. GENERON
  56. Genetech
  57. Genmab
  58. Gerresheimer
  59. Gilero
  60. GlaxoSmithKline
  61. Glenmark Pharmaceuticals
  62. Hanmi Pharmaceutical
  63. Heron Therapeutics
  64. Hetero Healthcare
  65. Il-Yang Pharm
  66. Insulet
  67. Ipsen
  68. IWA Consulting
  69. Janssen
  70. Kiniksa Pharmaceuticals
  71. Kymanox
  72. Kyowa Kirin
  73. Salvat Laboratories 
  74. LEO Pharma
  75. Lubrizol Life Science
  76. Lundbeck
  77. Medicago
  78. Medical Engineering Technologies
  79. MEDIcept
  80. Merck
  81. Milfra (Acquired by Nemera)
  82. Mithra Pharmaceuticals
  83. Mitsubishi Tanabe Pharma
  84. Momenta Pharmaceuticals
  85. MorphoSys
  86. NAMSA
  87. Nelson Labs
  88. NEUMA 
  89. NeuroDerm
  90. Nexus Pharmaceuticals
  91. Novartis
  92. Novocol Pharmaceuticals
  93. NubGenix
  94. Oncobiologics
  95. Otsuka Pharmaceutical
  96. Pace Analytical® Services
  97. Pfizer
  98. PharmaEssentia 
  99. Phillips-Medisize
  100. Piramal Enterprises
  101. PTC Therapeutics
  102. Regeneron
  103. RHEACELL
  104. Roche
  105. Samsung Bioepis
  106. Sandoz
  107. Sanofi
  108. Sanofi Pasteur
  109. scPharmaceuticals
  110. Seqirus
  111. Shire
  112. Special Pathogens Laboratory
  113. Sun Pharma
  114. Surpass
  115. Suttons Creek
  116. Swedish Orphan Biovitrum
  117. Takeda Pharmaceuticals
  118. Teva Pharmaceutical
  119. UCB Biopharma
  120. United Therapeutics
  121. US Department of Health and Human Services 
  122. Valeant Pharmaceuticals
  123. Velesco Pharmaceutical Services
  124. Vitaeris
  125. West Pharmaceutical Services
  126. WestView Capital Partners
  127. Wickham Micro
  128. WuXi AppTec
  129. Xeris Pharmaceuticals
  130. YL Biologics
  131. Zealand Pharma
  132. ZebraSci
  133. Zhejiang Huahai Pharmaceutical

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 8) n a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com